|
|
Volumn 24, Issue 15, 2014, Pages 3238-3242
|
|
Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part II
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
|
|
Author keywords
CAR model in SD rats; PPI deficit model; Pyrrolo 3,2 b pyridine; Pyrrolo 3,2 b quinoline; Sniffing versus climbing in mice
|
|
Indexed keywords
ETHER DERIVATIVE;
PHOSPHODIESTERASE INHIBITOR;
PHOSPHODIESTERASE XA INHIBITOR;
UNCLASSIFIED DRUG;
1-METHYL-3-(4-((3-(PYRIDINE-4-YL)PYRAZIN-2-YL)OXY)PHENYL)-1H-PYRROLO(3,2-B)PYRIDINE;
PDE10A PROTEIN, HUMAN;
PHOSPHODIESTERASE;
PYRAZINE DERIVATIVE;
PYRIDINE DERIVATIVE;
1 METHYL 3 [4 [[3 (PYRIDINE 4 YL)PYRAZIN 2 YL]OXY]PHENYL] 1H PYRROLO[3,2 B]PYRIDINE;
NEUROLEPTIC AGENT;
AEROBIC METABOLISM;
ARTICLE;
AVOIDANCE BEHAVIOR;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG BRAIN LEVEL;
DRUG DESIGN;
DRUG EFFICACY;
DRUG HYDROLYSIS;
DRUG METABOLISM;
DRUG POTENCY;
DRUG SCREENING;
DRUG STABILITY;
DRUG SYNTHESIS;
ESCAPE BEHAVIOR;
FEMALE;
IC 50;
IN VITRO STUDY;
MALE;
METHYLATION;
MITSUNOBU REACTION;
NONHUMAN;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHYSICAL CHEMISTRY;
PLASMA CLEARANCE;
POLYMERIZATION;
RAT;
STRUCTURE ACTIVITY RELATION;
SUZUKI REACTION;
ANIMAL;
CHEMICAL STRUCTURE;
CHEMISTRY;
DOG;
DOSE RESPONSE;
HAPLORHINI;
HUMAN;
METABOLISM;
MOUSE;
SPRAGUE DAWLEY RAT;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
AREA UNDER THE CURVE;
BRAIN LEVEL;
CONTROLLED STUDY;
DRUG HALF LIFE;
IC50;
MAXIMUM PLASMA CONCENTRATION;
SCHIZOPHRENIA;
TIME TO MAXIMUM PLASMA CONCENTRATION;
ANIMALIA;
MUS;
RATTUS;
RODENTIA;
ANIMALS;
DOGS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DESIGN;
ETHERS;
HAPLORHINI;
HUMANS;
MALE;
MICE;
MOLECULAR STRUCTURE;
PHOSPHODIESTERASE INHIBITORS;
PHOSPHORIC DIESTER HYDROLASES;
PYRAZINES;
PYRIDINES;
RATS;
RATS, SPRAGUE-DAWLEY;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 84904071181
PISSN: 0960894X
EISSN: 14643405
Source Type: Journal
DOI: 10.1016/j.bmcl.2014.06.028 Document Type: Article |
|
Times cited : (8)
|
|
References (20)
|
